Revolution Medicines Plummets 17% — The $30 Billion Deal That Vanished
Revolution Medicines experienced a 17% stock drop when Merck canceled a potential $30 billion acquisition. The episode discusses the valuation issues, the company's financial state despite zero revenue, and the potential impact of upcoming Phase 3 data for daraxonrasib.